Summary
Danaher's stock is currently undervalued at $109.
Danaher Business System (DBS) continues to show success in M&A and operations, as shown by DHR's increasing stock price.
Danaher Corporation will not be slowing its growth as M&A deals continue to be processed.
Investment Thesis:
Danaher Corporation (NYSE: DHR) has consistently shown success through its DBS strategy and acquisitions; however, the company still remains undervalued as the M&A growth has increased year over year. The company's key platforms and acquisitions in the biotechnology space including those of Pall and Beckman Coulter will continue to generate cash flows as innovation in the healthcare segment increases.
Company Overview
Danaher Corporation (NYSE:DHR) is a global conglomerate that designs, manufactures, and produces diverse lines of industrial and consumer products. The company has involvement in the professional, industrials, medical, and consumer products sectors. Since its spin-off, Danaher has restructured its business into four different segments: Dental, Life Science and Diagnostics, and Environmental and Applied solutions.
